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Monte Carlo investigation of the
characteristics of radioactive beams
for heavy ion therapy
Andrew Chacon1,2, Mitra Safavi-Naeini 1,2,3,4, David Bolst1, Susanna Guatelli1,4,
Daniel R. Franklin5, Yuma Iwao6, Go Akamatsu6, Hideaki Tashima6, Eiji Yoshida6,
Fumihiko Nishikido6, Atsushi Kitagawa6, Akram Mohammadi6, Marie-Claude Gregoire1,2,3,
Taiga Yamaya6 & Anatoly B. Rosenfeld1,4
This work presents a simulation study evaluating relative biological effectiveness at 10% survival
fraction (RBE10) of several different positron-emitting radionuclides in heavy ion treatment systems,
and comparing these to the RBE10s of their non-radioactive counterparts. RBE10 is evaluated as a
function of depth for three positron-emitting radioactive ion beams (10C, 11C and 15O) and two stable ion
beams (12C and 16O) using the modified microdosimetric kinetic model (MKM) in a heterogeneous skull
phantom subject to a rectangular 50 mm × 50 mm × 60 mm spread out Bragg peak. We demonstrate
that the RBE10 of the positron-emitting radioactive beams is almost identical to the corresponding
stable isotopes. The potential improvement in PET quality assurance image quality which is obtained
when using radioactive beams is evaluated by comparing the signal to background ratios of positron
annihilations at different intra- and post-irradiation time points. Finally, the incidental dose to the
patient resulting from the use of radioactive beams is also quantified and shown to be negligible.
Heavy ion therapy (HIT) is a relatively new cancer treatment modality, with several facilities operating or under
construction around the world1–3. A monoenergetic heavy ion beam deposits most of its energy within a narrow
depth range - known as the Bragg Peak - with the peak dose depth determined by the beam energy, ion species
and target composition4,5. Irradiation of the entire target volume is achieved using a range of particle energies,
either via a passive scatterer or a raster-scanned spot beam with varying energy. Due to the narrow depth range
of the Bragg peak, together with minimal lateral scattering and the high relative biological effectiveness (RBE) of
heavy ions, HIT delivers a highly conformal therapeutic dose to the target volume with a much lower entrance
dose than is possible with photon therapy. HIT achieves a lower entrance dose compared to proton therapy,
although unlike proton therapy, some dose is delivered beyond the distal edge of the target volume due to the
fragmentation tail.
The precision of HIT makes it particularly useful for treating deeply-situated tumours while minimising damage to adjacent healthy tissue4,6–8. However, due to the large dose gradients, deviations between the treatment
plan and the delivered dose distribution can result in significant adverse effects on healthy tissue, particularly if
the treatment region is in the proximity of an organ at risk (OAR). Accurate real-time measurement of spatial
dose distribution during irradiation will provide a mechanism for closed-loop control over the treatment process,
minimising errors between the treatment plan and the actual delivered dose.
During HIT, a fraction of the ions in the beam will undergo nuclear inelastic collisions. Fragmentation of
nuclei either from the primary beam or in the target and entrance path result in the production of a range of stable
and radioactive nuclei6. Some of these fragments are positron-emitting radionuclides, which continue to travel
a short distance in the target before coming to a stop, where they eventually decay. Measuring of the distribution
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of these secondary positron-emitting fragments offers a unique opportunity for nonÂinvasive, real-time and/or
offline quality assurance (QA) in heavy ion therapy via positron emission tomography (PET)9–16.
A large number of annihilation photons must be detected in order to obtain a PET image of sufficient quality
for useful treatment QA. The cross-sections for inelastic ion collisions depend on several parameters, including
incident ion species and energy, and the density and composition of the target17. These factors determine the
mix of fragments produced, which, in turn, determines the number and distribution of positron-emitting radionuclides resulting from each beam spill. To improve image quality, several authors have proposed the use of
positron-emitting radioactive nuclei (such as 11C, 15O or 10C) as the primary particle in the heavy ion beam. Most
primary particles will survive intact to decay via positron emission at their stopping point, corresponding to the
location of the Bragg peak. Therefore, for radioactive beams, the spatial distribution of the stopping points of primary particles is the dominant component of the PET image, while positron-emitting target and beam fragments
making up a secondary component.
Beamlines capable of producing beams of radioactive ion species such as 11C, 10C and 15O with sufficient dose
rates and beam purity for therapeutic use are currently under development at the National Institutes for Quantum
and Radiological Science and Technology (NIRS, QST) in Japan and other facilities around the world18–23.
In order to perform proper treatment planning with positron-emitting radioactive beams, and to understand
how their use will impact image-based QA, it is necessary to address three key research questions:
1. How does the relative biological effectiveness (RBE) of polyenergetic radioactive beams vary as a function of depth within a spread out Bragg peak, and how does this compare to the corresponding stable ion
species?
2. What quantitative differences are expected between the maps of positron annihilation resulting from treatment with stable and positron-emitting radioactive ion beams, and how will these impact the use of PET
images as an intra-treatment or post-treatment QA mechanism? and finally,
3. What additional dose will be received by the patient if a positron-emitting radioactive beam is used instead
of a stable beam?
In this work, simulations of a simple treatment plan (consisting of a flat biological dose in a
rectangular-prismatic primary treatment volume inside a human skull phantom) are performed for five primary
nuclei (three positron-emitting and two stable) using the Geant4 Monte Carlo toolkit. The values of RBE10 (RBE
at 10% survival fraction) are estimated across a range of depths along the beam path (in the entrance, SOBP and
tail regions) using Kase’s modified microdosimetric kinetic model (MKM)24–26. The validity of using Monte Carlo
simulations to evaluate RBE using the MKM has previously been established by Bolst et al.27,28; however, to our
knowledge, this is the first time that this approach has been applied to estimate the RBE10 of a polyenergetic radioactive beam. The method can easily be extended to other homogeneous or heterogeneous targets and heavy ion
species, and is a convenient and cost-effective alternative to in vitro experiments.
Monte Carlo simulation-based 2D maps of positron yield obtained in a skull phantom using a spread out
Bragg peak (with the same flat biological dose (in Gy(RBE)) delivered throughout the planned treatment volume)
are compared across all beam types. The distribution of positron production in the target volumes, as measured
during the beam-off periods during irradiation of the phantom with the radioactive and corresponding stable
heavy ion beams were measured, and the resulting signal to background ratios (SBRs) estimated. The chosen
physics models in the simulation are validated via experimental work conducted at NIRS’s HIMAC facility.
Finally, the additional dose to the patient resulting from the use of radioactive beams is estimated to determine
whether it poses any significant risk to the patient compared to the use of a stable ion beam.
The remainder of this paper is organised as follows. A summary of key related work, including a description
of the modified MKM which is adopted in this paper, is presented in Section 2. Details of the Monte Carlo simulations, including the phantom, physical and biophysical models used and the experimental validation of the
selected physics models, the implementation of a pseudo-clinical beamline and treatment plan for stable and
their corresponding radiactive ion beams are discussed in Section 3. Simulation results and analysis of the RBE10
values of stable and radioactive beams, the resulting positron yield maps and the incidental dose resulting from
the use of the radiactive beams are presented and discussed in Section 4. Conclusions and proposed future work
are presented in Section 5.

Related Work

The use of positron-emitting radioisotopes for heavy ion therapy has been investigated by a number of authors. In
2001, Urakabe et al. demonstrated that a positron-emitting 11C scanned spot beam could be directly used as the
therapeutic agent29. However, the estimate of RBE10 used to obtain a flat biological dose was based on an extrapolation of previously-reported results for 12C in water, which was assumed to extend to human tissue30. Iseki et
al. at NIRS used low-intensity monoenergetic 10C probe beams with between 10 4 and 10 5 particles per spill to
estimate the depth of the therapeutic 12C beam’s Bragg peak, while keeping the dose received during the range
measurement under 100 mGyE (a few percent of therapeutic dose)31. RBE of the radioactive beam was estimated
via simulation using the one-dimensional HIBRAC beam transportation code from Sihver et al. combined with
Kanai’s RBE model30,32,33. However, this work only considered monoenergetic 11C ion beams, and ignored the
effects of low-LET fragmentation products, which resulted in an overestimation of the RBE for 11C. Augusto et al.
used the FLUKA Monte Carlo toolkit to investigate the use of 11C beams either alone or in conjunction with 12C34.
It was found that for beams with equivalent energy per nucleon incident on the same water phantom, 11C and 12C
beams produce very similar fragmentation products, with the main differences being the relative yield of helium
ions and several boron isotopes. While this study demonstrated the potential of using 11C in heavy ion therapy, it
only considered monoenergetic beams of 11C at a fixed depth (100 mm) in a homogeneous water phantom. The
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Interaction

Energy Range

Geant4 Model/Package

Radioactive Decay

All energies

G4RadioactiveDecayPhysics

Particle Decay

All energies

G4Decay

Hadron Elastic

All energies

G4HadronElasticPhysicsHP

0–110 MeV

Binary Light Ion Cascade

Ion Inelastic
Neutron Capture
Neutron Inelastic

>100 MeV

QMDModel

0–20 MeV

NeutronHPCapture

0–20 MeV

NeutronHPInelastic

>20 MeV

Binary Cascade

Proton Inelastic

0–9.9 GeV

Binary Cascade

EM Interactions

All energies

G4EmStandardPhysics_option3

Table 1. Hadron physics models used in all simulations.

composition of the phantom, the isotope and the specific beam energy are important factors affecting the fragmentation processs and the spatial distribution of positron-emitting nuclei which results35,36.
These works demonstrate the potential for using positron-emitting beams both for radiotherapy and for range
verification. However, in order to conclusively establish their clinical utility, it is necessary to quantify their RBE
and evaluate the quality of the resulting PET image in a clinically relevant configuration, through the use of heterogenous tissue-equivalent phantoms and polyenergetic ion beams.
Relative biological effectiveness (RBE) is an empirically-derived ratio which can be used to predict the physical dose of a specific type of radiation which will result in the same cellular survival fraction as a reference dose
(typically a 200 keV X-ray beam)37,38. The complex dependencies of RBE on the energy and type of radiation, as
well the location of the target and the specific tissue types present, require the use of biophysical methods for
accurate theoretical estimation of RBE39–41. The Microdosimetric Kinetic Model (MKM), proposed by Hawkins
et al., is a widely-used method for estimating RBE in which the microdosimetric spectrum (f(y)) is measured
through the use of a tissue-equivalent proportional counter (TEPC)24. It was subsequently extended by Kase et al.
to relate the saturation-corrected dose-mean lineal energy ( y ⁎) to the radiation sensitivity coefficient α of the
linear quadratic model (LQM, measured in units of Gy−1 and Gy−2), such that the method can be applied to therapeutic heavy ion beams25,26,42. This modified MKM has been extensively validated for carbon ion therapy, and
also extended to proton and helium ion therapy25,26,42–44.
The RBE10 for an ion beam, defined as the ratio of the physical dose from a 200 kVp X-ray beam required to
achieve a cellular survival fraction of 10% (D(10,R)) to the ion beam dose resulting in the same cell survival fraction, can be derived using the microdosimetric spectra f(y), using (1), (2) and (3):
y 

−
∫ 1 − e ( y0 )  f (y )dy
2

y ⁎ = y02




∫ yf (y )dy

(1)

β0 ⁎
y
ρπrd2

(2)

α = α0 +

RBE10 =

2βD10, X ‐ray
α2 − 4β log (0.1) − α

(3)

For human salivary gland (HSG) tumour cells, the dose resulting in a survival fraction of 10%, D(10,R) is 5 Gy
for 200 kVp X-rays; the LQM radiation sensitivity coefficient values are α0 = 0.13 Gy−1 and β0 = 0.05 Gy−2. ρ and rd
are the density and the radius of the sub-cellular domain, and assumed to be 0.42 μm and 1 g/cm3, respectively25.
In this work, RBE10 is estimated using an extension to the modified MKM proposed by Bolst et al., whereby
the mean path length <l path> of the charged particles that cross the sensitive volume is introduced to account for
the directionality of the radiation field when deriving the microdosimetric spectra f(y) in a non-spherical sensitive volume, as opposed to the average chord length used in isotropic fields27,28.
Although estimates of the RBE10 for radioactive beams have been reported previously, these have been calculated using simplified analytic models with parameters interpolated/extrapolated from limited experimental data
from beams of stable isotopes in homogeneous targets45,46. The assumption that the RBE of radioactive ion species
can be estimated from its stable analog has not been previously demonstrated in the literature.

Method

All Monte Carlo simulations were performed using the Geant4 toolkit (version 10.2.p03)47,48. The hadronic physics models used in the simulations are listed in Table 1, while electromagnetic interactions were modelled using
the standard Geant4 option 3 physics constructor (G4EmStandardPhysics_option3). The hadronic physics processes and models are listed in Table 1.
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Figure 1. The experimental configuration used to estimate the depth-dose profile of the stable ion beams in
water, at the primary beam course (HIMAC, Japan); the radioactive beams were produced at the secondary
beam course (not shown in this image).

Phantom Name

Phantom material

Dimensions

PMMA phantom

PMMA

100 × 100 × 300 mm3

Water phantom

Water

250 × 250 × 250 mm3

Skull phantom

Bone

250 × 250 × 10 mm3

Brain Tissue (modelled as muscle)

250 × 250 × 240 mm3

Table 2. Phantom compositions.

Section 3.1 details the methods used to experimentally validate the Geant4 simulation. The phantoms used in
the simulations are described in detail in Section 3.2. In Sections 3.3, 3.4 and 3.5, the implementation of the modified MKM for the evaluation of the RBE10 of pseudo-clinical, polyenergetic carbon and oxygen beams and their
corresponding radioactive beams is described. Lastly, Section 3.6 describes a simulation study which examines
the yield of different positron-emitting radionuclides during and after the irradiation of a skull phantom with
radioactive and corresponding stable beams and introduces the metric used for the evaluation of the quality of
the resulting annihilation maps.

Experimental validation of the physics models. To validate the Monte Carlo physics models, several
simulations evaluating depth-dose profiles and positron-emitting radionuclide yield were performed and compared with measurements obtained from equivalent physical experiments.
All experiments were performed at the Heavy Ion Medical Accelerator in Chiba (HIMAC), Japan, with the
stable ion beams produced at the primary beam course, and the radioactive ion beams at the secondary beam
course19,23. The peak energies of the non-radioactive 12C and 16O ion beams, as measured at the beamline nozzle,
were 290 MeV/u and 400 MeV/u, respectively with an energy spread of σ = 0.2%. The peak energies of the radioactive 11C and 15O ion beams were 330 MeV/u and 290 MeV/u, respectively, each with an energy spread of σ = 5%.
The nominal transverse diameter of all beams was 2 mm full width at half maximum (FWHM).
Depth-dose relationship. The experimental configuration shown in Fig. 1 was used to compare the experimental and simulation-based depth-dose curves. The deposited energy was measured using a pre-calibrated cross
ionisation chamber (IC) with a sensitive volume of 36 mm3, inside a 300 × 300 × 300 mm3 water phantom23. The
IC was encased within a 0.5 mm PMMA casing and moved along the path of the beam using a motorised stage,
with an accuracy of 10 μm. The energy deposited within the ionisation chamber at each point along the beam was
normalised to the energy deposited at the entrance (i.e. at the front of the phantom). All depth measurements
were converted to water equivalent depth.
For the simulation study, each beam was modelled using a monoenergetic incident beam with a Gaussian
energy distribution, with the same peak energies and spreads as for the HIMAC beamlines. The simulated beams
entered the water phantom perpendicular to its front surface (see Table 2), with an air gap of 2.5 m between
the beamline nozzle and the phantom surface as per the corresponding experimental configuration. The energy
deposited was scored in the water phantom using 1 mm3 voxels and summed over a 36 mm3 volume equivalent to
the sensitive volume of the ionisation chamber used throughout the experimental measurements. Energy deposited in the sensitive volume (as a function of depth) was normalised to value observed at the entrance plateau.
Positron-emitting fragmentation product yield. The hadronic physics models of Geant4, including the Quantum
Molecular Dynamics (QMD) ion hadronic inelastic scattering and Radioactive Decay physics models, were validated by comparing the simulated and experimentally estimated yields of 11C, 10C and 15O, the three dominant
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Figure 2. The experimental configuration used in HIMAC, Japan, to validate the QMD ion hadronic inelastic
scattering model used in the simulations. The phantom is positioned within the field of view (FOV) such that
the calculated location of the Bragg peak (indicated by a red dot) is placed at the centre of the field of view
(CFOV).

positron-emitting radionuclides generated during irradiation of a 100 × 100 × 300 mm3 PMMA phantom by
monoenergetic 12C and 16O beams with energies of 290 MeV/u and 400 MeV/u, respectively.
The experimental configuration is shown in Fig. 2. The phantom was positioned such that the expected location
of the Bragg peak was aligned with the centre of the field of view in the OpenPET scanner14. 20 spills were used,
with a beam intensity of 1.0 × 109 particles per second (pps). In each spill, the beam was on for 1.9 seconds and off
for 1.4 seconds. List-mode PET data were collected intra-spill, and for 36 minutes after the final spill. Dynamic (4D)
images were reconstructed using the 3D ordinary Poisson ordered-subset-expectation-maximisation algorithm
(3D-OP-OSEM) with 1.5 × 1.5 × 1.5 mm3 voxels. Temporal frame lengths were chosen so as to be able to observe
decay over several half-lives of 11C, 10C and 15O. Yields of each positron-emitting radionuclide were estimated by fitting the parameters of a simple analytical model to the observed time-activity curves (TACs). Total activity as a function of time t in a volume with initial activities of 11C, 10C and 15O of A0,C11, A0,C10 and A0,O15, respectively, is given by
Atotal (t ) = A0, C11e− ln(2)t /TC11 + A0, C10 e− ln(2)t /TC10 + A0, O15 e− ln(2)t /TO15

(4)

where TC11, TC10 and TO15 are the respective half-lives of C, C and O. Total activity is measured as a function
of time across the build-up and Bragg peak region, defined as the region from the point at which the dose profile
has risen 5% above the entrance plateau to the point after which the profile is below 5% of the peak value.
The individual initial activities for each radionuclide are then estimated for both the simulation results and the
experimental data by fitting the model to the observed curve.
For the simulation studies, monoenergetic 12C and 16O beams were directed perpendicularly to the surface
of a simulated 10 × 10 × 30 cm3 PMMA with an air gap of 1.75 m between the beamline nozzle and the phantom
surface, matching the experimental configuration. Density, mean excitation, ionisation potential and dimensions
of simulated phantoms were chosen to match those used in the experiment. The spatio-temporal distributions of
positron-emitting nuclei, positron production and annihilation were recorded with a scoring volume resolution
of 1.5 mm, corresponding to the voxel dimensions in the experimental PET images. Simulated yield profiles were
convolved with a Gaussian filter, with its FWHM equal to the estimated OpenPET spatial resolution (3.5 mm)14.
11

10

15

Phantom geometry.

The phantoms used in the simulation were rectangular prisms with compositions as
listed in Table 2. All material compositions were based on data from the National Institute of Standards and
Technology (NIST) database49.

Estimation of RBE10 for a pseudo-clinical SOBP. To evaluate and compare the RBE10 of polyenergetic
stable and positron-emitting radioactive beams, sensitive 1 mm × 1 mm × 10 μm volumes were defined every
100 μm along the path of the beam. The lineal energy deposition spectrum in each volume for all interactions
(f(y)) was stored and used to calculate the RBE10 at that point, using (3) (equivalent results for monoenergetic
carbon and oxygen ion beams with the energies listed in Supplementary Table S1 are presented in Supplementary
Table S2). A correction factor 1.05 were used to account for the difference in stopping power and density of water
relative to brain tissue.
A simple variance analysis method was used to estimate a sufficient number of primary particles to use in the
simulations. M test simulations were conducted, each with N primary particles, with RBE estimated for each simulation and the mean and standard deviation (SD) calculated across the M simulations. The standard deviation
should approach zero as N tends to infinity; therefore, in this experiment, N was progressively doubled with a
fixed value of M = 50 until the ratio of standard deviation to mean was less than an arbitrary threshold of 1%. This
analysis suggested that N = 107 would be sufficient to get a good estimate of RBE (95% probability of the estimated
RBE being within ±2% of the true RBE).
Carbon. The spectrum for the simulated carbon beams was generated using an experimentally-validated
model of the passively-scattered 12C beamline at HIMAC, which is known to produce a flat biological dose across
a 60 mm depth range50. The spectra of the positron-emitting radioactive beams (10C and 11C) were based on the
Scientific Reports |
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12
C spectrum from this beamline, by determining the energies for which the Bragg peaks of monoenergetic radioactive ion beams where located at the proximal and distal edges of the desired SOBP, and linearly mapping the
weights of the energies of the 12C SOBP spectrum to this range of energies. Finally, the SOBPs were compared and
confirmed to both correspond to the planned depths.

Oxygen.

Currently a validated model of the 16O beamline does not exist. Therefore, generation of the 60 mm
flat biological dose SOBP in the target depth range was achieved by performing monoenergetic Monte Carlo
simulations of an 16O beam at a range of energies (177, 237, 297, 345 and 418 MeV/u), and evaluating the RBE10
as a function of depth for each energy using the modified MKM (see Section 3.3 and Supplementary Table S2).
This RBE was used to convert the physical dose deposited in the simulations to an estimated biological dose for
the 5 evaluated energies. Profiles were then generated for other intermediate energies by interpolating between
the simulated values in increments of 1 MeV/u. Finally, the target flat biological dose was achieved by adjusting
the weights of each of these profiles such that a flat biological dose rate of 5 Gy(RBE)/min was achieved within the
target depth range. The spectra of the positron-emitting radioactive beam (15O) was based on the 16O spectrum,
with energies scaled such that the SOBP was positioned in the desired depth range (as per carbon).

Positron-emitting radionuclide yield study. The impact of using positron-emitting primary beams on

interspill and post-irradiation image quality was evaluated by comparing the spatial distributions of positron
decays observed in the simulation over several different intervals during treatment of the skull phantom. A simple
treatment plan was designed for each primary particle type, aimed at producing a constant biological dose rate
of ≈5 Gy(RBE)/min in a depth range of 78–138 mm within a skull phantom. A total of 1 × 109 primary particles
were used in each simulation. As for the experimental validation study, twenty spills were simulated, with the
beam on for 1.9 seconds and off for 1.4 seconds.
The distributions of positron decays were acquired for each beam type between the first and second spill, during the first five inter-spill intervals, and in the five minutes following the final spill.
The contrast-to-noise ratios (CNRs) between the inside and outside of the proximal, distal and upper lateral
edges of the SOBP are computed for each image. The CNR provides a metric for objectively comparing the specificity with which the irradiated region is delineated, and is defined as:
CNR =

μa − μb
2
2
(σa + σb

(5)

where μa and μb are the mean signal amplitudes and σa and σb are the standard deviations of the image intensity
in two regions a and b of the image51,52.

Results and Discussion

Physics model validation. Experimental and simulation-based depth-dose curves are shown in Fig. 3; the

difference between the locations of the Bragg peaks obtained from the simulated and the experimental 12C, 16O,
C and 15O depth-dose profiles were 0.8 mm, 0.24 mm, 0.37 mm and 0.43 mm, respectively.
The experimental and simulation yields of 10C, 11C, and 15O produced during the irradiation of a PMMA
phantom using a 290 MeV/u 12C beam and a 400 MeV/u 16O beam are expressed as a percentage of the total
positron-emitting radionuclide yield and are listed in Table 3.
The close agreement between the experimental and simulated normalised depth-dose profiles and the relative
yield estimations of the positron-emitting fragments demonstrate the validity of the simulation model. The small
differences between the experimental and simulated depth dose profiles for radioactive primary particles may be
due to an underestimation of the initial energy spread, heterogeneity of the beryllium target leading to contamination with other fragments and systematic errors introduced by the ionisation chamber measurements.
11

RBE and biological dose in Gy(RBE). Figure 4 presents a comparison of RBE10 as a function of depth
for the positron-emitting radioactive beams and for the corresponding stable isotope beams (for clarity, RBE10
values are shown at depth increments of 3 mm; refer to Supplementary Spreadsheet 1 for a full list of RBE10 values evaluated at 100 μm intervals for all ion species). In each case, the mean RBE10s of the stable and radioactive
beams are well within each others’ 95% confidence interval. Radioactive-to-stable RBE10 ratios are also shown,
with the mean values remaining very close to 1.0 in the entrance and SOBP. The larger confidence intervals in the
tail region are due to very little energy being deposited beyond the end of the SOBP (as expected for heavy ion
beams), resulting in significant statistical noise.
Table 4 lists numerical values of the RBE10 obtained at the entrance, the beginning, middle and end of the
SOBP, and tail region for each beam type. The mean and standard deviations presented are calculated over 11 consecutive 100 μm deep sample volumes along the beam path centred about the listed depth. In all cases, the mean
RBE10s for the radioactive and corresponding stable ion beams are within one standard deviation of each other.
The significance of this result is that it indicates that the evaluated radioactive ion beams are comparable to
their non-radioactive counterparts in terms of relative biological effectiveness. Heavy ion therapy with any of
the radioactive ion species examined in this study should be feasible, with only minimal changes to the current
treatment planning algorithms required to account for the small differences in RBE10.
Positron yield.

Figure 5 shows the 2D annihilation maps obtained during and after the simulated delivery
of 5 Gy(RBE) for each beam type to the target volume within the skull phantom. Images in the first column correspond to data acquired during the first beam-off interval (i.e. after one spill), the centre column show images
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Figure 3. Experimental and simulated energy deposited in the sensitive volume plotted as a function of depth
for the 12C, 16O, 11C and 15O ion beams. The deposited energy is normalised to value observed at the entrance
plateau.

Primary
beam

Energy
(MeV/u)

Relative Yield (%)
Isotope
C

11

C

12

290

5±3

4±2

O

15 ± 6

14 ± 8

C

44 ± 10

43 ± 10

C

7±7

7±5

O

49 ± 14

50 ± 10

11

O

400

Experimental
82 ± 9

C

10
15

16

Simulation
80 ± 8

10
15

Table 3. Relative yields of positron-emitting nuclei in experiment and simulation.

following 5 spills, and finally, the last column shows images acquired during the five minutes (300 seconds) immediately after the completion of the 20th (and final) spill.
The CNRs of the inside and outside of the proximal, distal and upper lateral boundaries of the SOBP images
in Fig. 5 are listed in Table 5.
Positron annihilation maps acquired at different stages of the treatment process clearly demonstrate the potential improvements in range-verification QA that can be obtained with radioactive ion beams. Following a single
spill, the boundaries of the SOBP are very clearly visible in the cases of 10C and 15O (Fig. 5(a,j)), due to their short
half-lives (19.29 seconds and 122.24 seconds, respectively). The images from the 10C simulation also exhibit the
the highest CNR values for all boundaries after both 1 and 5 spills (i.e. the delivery of 5% and 25% of the total
planned dose) and 5 minutes after the delivery of the full treatment for the distal boundary. 15O also exhibits an
excellent CNR following a 5 minute acquisition, demonstrating the best results for proximal and distal edge. The
two stable beams produce images which are indistinct in comparison to any of the radioactive beam images. Due
to its half life of 20.334 minutes, only a small number of positron annihilations resulting from decays of 11C are
observed within the first beam-off period (Fig. 5(d)). The distal edge can be clearly seen, however the proximal
edge is indistinct. Finally, in the long post-irradiation image acquisition (right column in Fig. 5), most primaries
from the 10C and 15O beams have decayed, resulting in very similar high-contrast images. A substantial number
of primaries have now decayed in the case of 11C, resulting in the emergence of a well-defined edges to the SOBP;
it is expected that a 11C beam with a post-irradiation image acquisition of 20 minute or more will result in very
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Figure 4. Biological dose, physical dose and RBE10 for positron-emitting radioactive beams, together with the
ratio of radioactive-beam RBE10 to stable-beam RBE10, each shown as a function of depth within the phantom.
The objective is a uniform dose within a 60 mm SOBP, from 78 to 138 mm depth. For carbon, 12C is shown in
red, with 11C and the ratio of 11C: 12C shown in green, and 10C and the ratio of 10C:12C shown in blue. 16O is
shown in red, while both 15O and the ratio of 15O: 16O is shown in green. All confidence intervals are 95% (two
standard deviations).

Region

Depth
(mm)

Entrance

12

C RBE10

C RBE10

11

C RBE10

10

O RBE10

16

15

O RBE10

μ

σ

μ

σ

μ

σ

μ

σ

μ

σ

50

1.32

0.0577

1.31

0.0646

1.30

0.0511

1.51

0.0455

1.50

0.0469

Start of SOBP

81

1.61

0.184

1.61

0.182

1.56

0.148

1.84

0.137

1.84

0.173

Middle of SOBP

111

1.80

0.202

1.79

0.199

1.76

0.235

2.05

0.163

2.05

0.190

End of SOBP

131

2.21

0.251

2.23

0.258

2.20

0.256

2.59

0.215

2.46

0.187

Tail

171

1.15

0.396

1.12

0.317

1.12

0.365

1.28

0.501

1.27

0.407

Table 4. Means and standard deviations of the RBE10 for each beam evaluated at five depths (entrance, start,
middle and end of SOBP, and tail). At each depth, RBE10 is evaluated in 11 adjacent sensitive volumes (every
100 μm along the path of the beam) and the mean and standard deviation calculated.

high CNRs due to its longer half-life. By contrast, after a 5 minute acquisition, the distal and proximal edges of the
SOBP remain indistinct in the case of 12C. 16O exhibits a more well-defined distal edge to its SOBP compared to
12
C, however, the proximal edge is again poorly defined.
The images also demonstrate one of the key differences between the radioactive and stable beams. For radioactive beams, positron annihilations principally occur in the vicinity of the stopping point of the primary particle.
The intensity of the decay radiation observed in a PET image is therefore proportional to the number of primary
particles which have arrived at that particular depth. The energy weightings required to achieve a flat biological
dose have a bias towards higher energies (since more deeply-penetrating high-energy particles also deposit an
entrance dose which is added to the dose deposited by lower energy beams). Therefore, the distal edge of the
SOBP can be expected to be much brighter than the proximal edge, as is clearly evident in the images from the
radioactive beams. By contrast, the contribution of primary or target fragmentation, which is relatively minor for
the radioactive beams, is the only source of positrons in the case of the stable beams, and positron-emitting fragmentation products are produced to a varying extent along the entire length of the beam path (see Supplementary
Tables S3 and S4). Therefore, the stable beams exhibit a flatter (although not completely flat) activity distribution
in the SOBP, and weaker contrast between the SOBP and the entrance region.

Radiation dose to patients. Given the superiority of positron-emitting radioactive beams for intra- and
post-treatment QA imaging, it is also important to consider whether or not the use of such beams would have
any unintended side effects for the patient. From this perspective, the main difference for the patient is that an
additional radiation dose will result from the use of a radioactive beam. The dose resulting from the decay of a
positron-emitting radionuclide includes the kinetic energy of the positrons together with the 511 keV gamma
photons resulting from their eventual annihilation; for a 11C beam, a 70 Gy(RBE) dose delivered to a 100 mm
cubic treatment volume would require approximately 2.3 × 1011 particles, distributed throughout the treatment
volume. This corresponds to an initial activity concentration of 1.3 MBq/cc, which is comparable to tissue concentrations of radiotracer which would be used in diagnostic 11C clinical PET imaging, and would deliver a biological
dose‘ within the treatment volume of the order of 3–10 mSv. The additional dose rapidly falls off outside the treatment volume, and would be insignificant compared to the dose due to lateral scattering of particles.
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Figure 5. 2D positron annihilation maps resulting from 5 Gy(RBE) irradiation of the skull phantom, during
and after irradiation: after 1 of 20 beam spills (5% of the planned dose - first column), 5 of 20 beam spills (25%
of the planned dose - centre column) and 5 minutes post full-treatment (right column).

Proximal Edge
C

10

5 min

1 spill

5 spills

5 min

1 spill

5 spills

5 min

156.47

332.99

122.36

120.26

286.72

190.95

125.38

338.18

335.90

9.7344

C

4.5779

12

O

15

O

16

Distal Edge

5 spills

C

11

Lateral Edge

1 spill

28.398
3.7561

19.567
8.2736
79.051
8.7385

57.338

17.731

39.356

12.979

11.034

19.265

201.99
15.572

72.384
14.183

133.94

108.26
21.380
216.50

23.685

26.484

15.415
2.9674
53.606
5.6323

39.075
4.6759
85.169
9.5223

202.55
6.8661
233.24
14.268

Table 5. Contrast-to-noise ratios (CNRs) corresponding to Fig. 5; the highest CNR value in each column is
highlighted in bold.
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Conclusion

This work aimed to quantitatively evaluate the therapeutic potential of positron-emitting radioactive heavy
ion beams; in particular, with regard to the relative biological effectiveness of the beams compared to their
non-radioactive counterparts, the spatial distribution of the positron-emitting annihilations generated during
and after irradiation of the target, and the incidental dose to the patient. Monte Carlo simulations of heavy ion
therapy using a pseudo-clinical spread out Bragg peak constructed with positron-emitting radioactive beams of
11
C, 10C and 15O as well as stable 12C and 16O were undertaken with the Geant4 toolkit.
The simulation physics model was validated through a comparison of depth-dose curves for monoenergetic
11
C, 12C, 15O and 16O beams and relative yield estimations of the positron-emitting fragments produced within the
build-up and the Bragg peak region with experimental data for 12C and 16O obtained from the HIMAC facility in
Japan. The maximum difference between the location of maximum dose in the simulation and experimental data
was 0.8 mm, while the maximum difference in mean relative yields of the secondary positron-emitting fragments
was 2%.
The radiobiological effectiveness (RBE10) of each beam was calculated for an SOBP extending from depths of
78 to 138 mm in a skull phantom using the modified microdosimetric kinetic model (MKM). The RBE10 of the
radioactive ion beams was found to be within one standard deviation of the corresponding non-radioactive ion
beams for all energies, indicating that the therapeutic efficacy of such beams should be very similar to beams of
the corresponding non-radioactive ion.
Finally, the additional dose to the patient resulting from the use of radioactive beams was estimated to determine whether it poses any unreasonable risk to the patient compared to the use of a stable ion beam. The additional dose was found to be comparable to that received during diagnostic clinical PET, and therefore negligible
compared to the dose delivered to the target volume or surrounding tissues during the radiotherapy procedure.
In summary, positron-emitting radioactive heavy ions are approximately equivalent to the corresponding stable isotope with respect to expected therapeutic properties in heavy ion radiotherapy, while being greatly superior
to non-radioactive beams in terms of the potential for accurately imaging the treatment volume during and after
treatment. The substantial increase in positron yield offered by positron-emitting radioactive beams for the same
biological effective dose will allow the boundaries of the spread out Bragg peak in a PET image to be unambiguously identified, making the use of positron-emitting radioactive ions a compelling choice for heavy ion therapy.

Data Availability

All data generated or analysed during this study are included in this published article (and its Supplementary
Information Files) or are available from the corresponding author on reasonable request.
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